← Human Trials & Peer-Reviewed Studies
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry
Plain-language guide to PMID 29355551 (2018): multicenter observational study of BNP (Nesiritide).
Key Facts
- PMID
- 29355551
- Journal
- Chest
- Year
- 2018
- Study type
- Observational Study
- Authors
- Frantz RP et al. (10 authors)
- DOI
- 10.1016/j.chest.2018.01.009
What This Study Did, in Plain Language
What Was Tested
This observational study looks at BNP (Nesiritide).
Its impact on long-term overall survival (OS) was investigated in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL), a 5-year observational, multicenter, US registry of patients with PAH.
Why It Was Studied
Plasma brain natriuretic peptide (BNP) level is a prognostic biomarker in pulmonary arterial hypertension (PAH).
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
Patients were ≥ 18 years of age, met right heart catheterization criteria at rest, had World Health Organization group I PAH, and had BNP measurement at enrollment.
OS was compared in patients with low (≤ 340 pg/mL) vs high (> 340 pg/mL) BNP at baseline; changes between baseline and last assessment were also examined.
How the Study Was Run
The researchers set it up as a multicenter study.
Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.
Optimal BNP threshold was obtained via receiver operating characteristic curve analysis.
What Was Measured
Plasma brain natriuretic peptide (BNP) level is a prognostic biomarker in pulmonary arterial hypertension (PAH).
Topics PubMed links to this paper include Biomarkers, Hypertension, Pulmonary, Natriuretic Peptide, Brain, Prognosis, Pulmonary Wedge Pressure, Registries and Risk Assessment.
Author keywords: brain natriuretic peptide, mortality, pulmonary arterial hypertension and survival.
What This Means in Plain Language
The paper is a multicenter study of BNP (Nesiritide).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (Chest), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.